期刊文献+

耐药结核病研究进展 被引量:8

下载PDF
导出
摘要 耐药结核病(MDR-TB)指至少耐异烟肼(INH)和利福平(RFP)两种药物的结核病,其中原发性MDR-TB是指未结受过抗结核治疗者首次感染MDR-TB菌株而发生的MDR-TB[1]。近年来,MDR-TB流行与传播使本已严峻的全球结核病防治形势变得更加紧迫[2]。美国约有13%的新发患者至少耐一种以上抗结核药物,约3.2%的患者耐INH和RFP[3]。
出处 《山东医药》 CAS 北大核心 2011年第3期109-110,共2页 Shandong Medical Journal
  • 相关文献

参考文献8

二级参考文献48

  • 1张天民.抗结核药物研究进展和展望[J].结核病与胸部肿瘤,2004(2):147-151. 被引量:5
  • 2张庆和.耐多药结核病的治疗现状[J].临床肺科杂志,2005,10(3):372-373. 被引量:9
  • 3马屿.耐多药结核病及其防治[J].临床肺科杂志,2005,10(2):137-140. 被引量:118
  • 4Centers for Disease Control and Prevention ( CDC ). Extensively drug-resistant tuberculosis--United States, 1993-2006. MMWR Morb Mortal Wkly Rep, 2007, 56:250-253.
  • 5Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet, 2006, 368 : 1575-1580.
  • 6Shah NS, Wright A, Drobniewski F, et al. Extreme drug resistance in tuberculosis (" XDR-TB "): global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. Int J Tuberc Lung Dis, 2005,9 Suppl 1 :S77.
  • 7Hohz TH, Riekstina V, Zarovska E, et al. XDR-TB : extreme drug-resistance and treatment outcome under DOTS-Plus, Latvia, 2000-2002. Int J Tubere Lung Dis, 2005, 9 Suppl 1 : S258.
  • 8Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep, 2006,55:301-305.
  • 9Centers for Disease Control and Prevention ( CDC ). Extensively drug-resistant tuberculosis--United States, 1993-2006. MMWR Morb Mortal Wkly Rep, 2007, 56:250-253.
  • 10Banerjee R, Allen J, Westenhouse J, et al. Extensively drug- resistant tuberculosis in california, 1993-2006. Clin Infect Dis, 2008,47:450-457.

共引文献207

同被引文献59

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部